These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36153243)

  • 21. Prospective comparison and 1-year follow-up of a single endoscopic subureteral polydimethylsiloxane versus dextranomer/hyaluronic acid copolymer injection for treatment of vesicoureteral reflux in children.
    Oswald J; Riccabona M; Lusuardi L; Bartsch G; Radmayr C
    Urology; 2002 Nov; 60(5):894-7; discussion 898. PubMed ID: 12429323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute and delayed vesicoureteral obstruction after endoscopic treatment of primary vesicoureteral reflux with dextranomer/hyaluronic acid copolymer: why and how to manage.
    García-Aparicio L; Rodo J; Palazon P; Martín O; Blázquez-Gómez E; Manzanares A; García-Smith N; Bejarano M; de Haro I; Ribó JM
    J Pediatr Urol; 2013 Aug; 9(4):493-7. PubMed ID: 23507288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Learning from the learning curve: factors associated with successful endoscopic correction of vesicoureteral reflux using dextranomer/hyaluronic acid copolymer.
    Dave S; Lorenzo AJ; Khoury AE; Braga LH; Skeldon SJ; Suoub M; Farhat W; Pippi Salle JL; Bägli DJ
    J Urol; 2008 Oct; 180(4 Suppl):1594-9; discussion 1599-600. PubMed ID: 18710756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence and risk factors for calcification after dextranomer/hyaluronic acid (Dx/HA) copolymer injection for vesicoureteral reflux.
    Soria-Gondek A; Martín-Solé O; Pérez-Bertólez S; Martín-Lluís A; Tarrado-Castellarnau X; García-Aparicio L
    J Pediatr Urol; 2021 Jun; 17(3):401.e1-401.e9. PubMed ID: 33663999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective study of polydimethylsiloxane vs dextranomer/hyaluronic acid injection for treatment of vesicoureteral reflux.
    Moore K; Bolduc S
    J Urol; 2014 Dec; 192(6):1794-9. PubMed ID: 24928269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Are there predictive factors for the outcome of endoscopic treatment of grade III-V vesicoureteral reflux with dextranomer/hyaluronic acid in children?
    Altug U; Cakan M; Yilmaz S; Yalçinkaya F
    Pediatr Surg Int; 2007 Jun; 23(6):585-9. PubMed ID: 17356857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endoscopic treatment for vesicoureteral reflux: how important is technique?
    Watters ST; Sung J; Skoog SJ
    J Pediatr Urol; 2013 Dec; 9(6 Pt B):1192-7. PubMed ID: 23769202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of vesicoureteral reflux using endoscopic injection of nonanimal stabilized hyaluronic acid/dextranomer gel: initial experience in pediatric patients by a single surgeon.
    Yu RN; Roth DR
    Pediatrics; 2006 Aug; 118(2):698-703. PubMed ID: 16882825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ureteral Obstruction After Endoscopic Treatment of Vesicoureteral Reflux: Does the Type of Injected Bulking Agent Matter?
    Friedmacher F; Puri P
    Curr Urol Rep; 2019 Jul; 20(9):49. PubMed ID: 31289951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endoscopic treatment of moderate and high grade vesicoureteral reflux in infants using dextranomer/hyaluronic acid.
    Puri P; Mohanan N; Menezes M; Colhoun E
    J Urol; 2007 Oct; 178(4 Pt 2):1714-6; discussion 1717. PubMed ID: 17707016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dextranomer/hyaluronic acid for pediatric vesicoureteral reflux: systematic review.
    Routh JC; Inman BA; Reinberg Y
    Pediatrics; 2010 May; 125(5):1010-9. PubMed ID: 20368325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome analysis of mini-ureteroneocystostomy versus dextranomer/hyaluronic acid copolymer injection for unilateral vesicoureteral reflux.
    Ashley R; Vandersteen D
    J Urol; 2008 Oct; 180(4 Suppl):1611-3; discussion 1614. PubMed ID: 18710741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Open ureteroneocystostomy after failed endoscopic injection with three different bulking agents for the treatment of vesicoureteral reflux.
    Sencan A; Yıldırım H; Ozkan KU; Uçan B; Hoşgör M
    J Pediatr Surg; 2014 Nov; 49(11):1652-5. PubMed ID: 25475812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changing bulking agent may require change in injection volume for endoscopic treatment of vesicoureteral reflux.
    Tekin A; Yagmur I; Tiryaki S; Dokumcu Z; Ulman I; Avanoglu A
    Int Braz J Urol; 2018; 44(6):1194-1199. PubMed ID: 30325612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Late ureteral obstruction after endoscopic treatment of vesicoureteral reflux with polyacrylate polyalcohol copolymer.
    Şencan A; Yıldırım H; Özkan KU; Uçan B; Karkıner A; Hoşgör M
    Urology; 2014 Nov; 84(5):1188-93. PubMed ID: 25443932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endoscopic treatment with dextranomer-hyaluronic acid for vesicoureteral reflux: histological findings.
    Stenberg A; Larsson E; Läckgren G
    J Urol; 2003 Mar; 169(3):1109-13. PubMed ID: 12576864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endoscopic treatment of primary grade V vesicoureteral reflux using hyaluronic acid copolymer (DX/HA).
    Hunziker M; Mohanan N; D'Asta F; Puri P
    Pediatr Surg Int; 2010 Oct; 26(10):977-9. PubMed ID: 20625750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term followup of children treated with dextranomer/hyaluronic acid copolymer for vesicoureteral reflux.
    Läckgren G; Wåhlin N; Sköldenberg E; Stenberg A
    J Urol; 2001 Nov; 166(5):1887-92. PubMed ID: 11586255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endoscopic Injection of Dextranomer/Hyaluronic Acid as First Line Treatment in 851 Consecutive Children with High Grade Vesicoureteral Reflux: Efficacy and Long-Term Results.
    Friedmacher F; Colhoun E; Puri P
    J Urol; 2018 Sep; 200(3):650-655. PubMed ID: 29551405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The cost-effectiveness of dextranomer/hyaluronic acid copolymer for the management of vesicoureteral reflux. 2. Reflux correction at the time of diagnosis as a substitute for traditional management.
    Benoit RM; Peele PB; Cannon GM; Docimo SG
    J Urol; 2006 Dec; 176(6 Pt 1):2649-53; discussion 2653. PubMed ID: 17085183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.